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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of relapsed large cell non-Hodgkin’s
lymphoma
Diagnosis
. Early relapse (<12 months) of a histologically well-estab-
lished large cell lymphoma does not require repeat biopsy
unless clinical presentation mandates exclusion of a second
malignancy. In later relapses histological verification of
diagnosis is mandatory to exclude the possibility of follicu-
lar lymphoma.
. In patients with late relapse or lack of initial adequate
immune histochemistry, verification by histology should be
done and should include the use of B-cell and T-cell mar-
kers since their presence may offer specific treatment
options.
. The histological report should give the diagnosis according
to the World Health Organisation classification.
Staging and risk assessment
. Patients still amenable to curative therapy should have at
least a CT-scan of the abdomen, a chest X-ray or a CT-scan
of the chest, and a bone marrow aspirate and biopsy. A
diagnostic spinal tap directly combined with a first prophy-
lactic instillation of cytarabine or methotrexate should be
considered in high-risk patients showing more than two
adverse parameters according to international prognostic
index (IPI), especially if involvement of bone marrow,
testis, the spine, or the base of the skull is present [V, D].
. A complete blood count, a routine blood chemistry includ-
ing LDH and uric acid as well as a screening test for HIV
and hepatitis B and C are required.
. The staging at relapse is given according to the Ann Arbor
system with mentioning of bulky disease [III, A].
. The cumulative dose of anthracyclines used in first line
therapy has to be specified (in mg/m2). If further anthracy-
clines are to be used, echocardiography or MUGA scans
for quantification of the ejection fraction should be done
[V, D].
. For prognostic purposes, the IPI should be established [III,
A].
Treatment plan
. In CD20-positive B-cell lymphomas the use of rituximab
has shown considerable single agent activity even after
failed transplantation and may be combined with conven-
tional or high-dose salvage chemotherapy as listed below.
However, its impact upon response rate and long-term
prognosis still requires confirmation from randomized trials.
. The following recommendations apply to patients with
adequate, anthracycline-containing first-line therapy.
Treatment with curative intent
. In suitable patients (no major organ dysfunction, age below
approximately 65 years) conventionally-dosed salvage che-
motherapy followed by high-dose treatment with stem cell
support in responsive patients is recommended [II, A]. Any
of the published salvage regimens such as (R-) DHAP, (R-)
ESHAP, (R-) EPOCH, (R-) ICE, etc. may be adequate since
comparative trials are lacking. Also, the choice of the high-
dose regimen depends on local experience. Additional
involved field or iceberg radiation may be used.
Treatment in patients not suitable for high-dose
therapy
. The same conventionally-dosed salvage regimens may be
used and may be combined with involved field radiotherapy.
Individualized palliative care may be needed in elderly,
co-morbid or HIV-positive patients.
Response evaluation
. Adequate radiological tests should be done after 2–4 cycles
of salvage therapy, i.e. before autologous stem cell collec-
tion and high-dose therapy, and after the end of all therapy.
. An initially-pathologic bone marrow aspirate/biopsy or
spinal tap should be repeated at the end of treatment.
Follow-up
. History and physical examination every 3 months for 2
years, every 6 months for 3 more years, and then once a year
with attention to development of secondary tumors [V, D].
. Full blood count at 3, 6, 12, and 24 months, then only as
needed for evaluation of suspicious symptoms or clinical
findings in those patients suitable for further therapy [V, D].
. Evaluation of thyroid function (TSH) in patients with
irradiation to the neck at 1, 2, and 5 years [III, C].
. After having received chest irradiation at premenopausal
age, especially at an age <25 years, women should be
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screened for secondary breast cancers clinically [III, A] and,
after the age of 40–50 years, by mammography [III, C].
. Minimal adequate radiological examinations (with a CT
scan at least once) at 3, 6, 12, and 24 months, then as
needed for evaluation of suspicious symptoms or clinical
findings in those patients suitable for further therapy [V, D].
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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